ABT-RTA 408 is a small molecule Nrf-2 activator being investigated to treat multiple cancers. It is being developed in conjunction with Reata.

Type of Molecule

Small Molecule

Target

Nrf-2

Region

n/a

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Melanoma New Indication Phase 1